Comparative Pharmacology
Head-to-head clinical analysis: RENFLEXIS versus YUFLYMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENFLEXIS versus YUFLYMA.
RENFLEXIS vs YUFLYMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Renflexis (infliximab-abda) is a chimeric monoclonal antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory activity. It inhibits TNFα binding to its receptors (TNFR1 and TNFR2), reducing inflammatory cell migration, cytokine production, and tissue damage.
Tumor necrosis factor (TNF) alpha blocker; a monoclonal antibody that binds to soluble and membrane-bound TNF-alpha, inhibiting its interaction with TNF receptors and reducing inflammatory responses.
5 mg/kg intravenously over at least 2 hours at 0, 2, and 6 weeks, then every 8 weeks.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
None Documented
None Documented
Terminal elimination half-life approximately 18-21 days (mean ~20 days) in patients with rheumatoid arthritis; supports every-8-week dosing interval.
Terminal elimination half-life approximately 10-20 days (mean 14 days), supporting every-other-week dosing intervals.
Primarily eliminated via reticuloendothelial system degradation; renal excretion accounts for <1% of dose as unchanged drug; no significant biliary or fecal excretion.
Adalimumab is primarily degraded into small peptides and amino acids via catabolic pathways; renal excretion of intact antibody is negligible. No biliary or fecal elimination data available.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor